U.S. markets open in 3 hours 49 minutes
  • S&P Futures

    3,756.25
    -9.25 (-0.25%)
     
  • Dow Futures

    30,816.00
    -62.00 (-0.20%)
     
  • Nasdaq Futures

    12,400.75
    -54.25 (-0.44%)
     
  • Russell 2000 Futures

    2,135.40
    -9.10 (-0.42%)
     
  • Crude Oil

    65.12
    +1.29 (+2.02%)
     
  • Gold

    1,692.50
    -8.20 (-0.48%)
     
  • Silver

    25.31
    -0.16 (-0.61%)
     
  • EUR/USD

    1.1937
    -0.0041 (-0.35%)
     
  • 10-Yr Bond

    1.5500
    0.0000 (0.00%)
     
  • Vix

    28.31
    +1.64 (+6.15%)
     
  • GBP/USD

    1.3801
    -0.0093 (-0.67%)
     
  • USD/JPY

    108.5190
    +0.5430 (+0.50%)
     
  • BTC-USD

    47,036.17
    -2,021.23 (-4.12%)
     
  • CMC Crypto 200

    941.51
    -45.70 (-4.63%)
     
  • FTSE 100

    6,657.18
    +6.30 (+0.09%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

AtriCure: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of AtriCure (NASDAQ:ATRC) fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 51.35% year over year to ($0.18), which beat the estimate of ($0.28).

Revenue of $57,725,000 declined by 5.86% from the same period last year, which missed the estimate of $58,100,000.

Guidance

Atricure Sees FY21 Adj. EBITDA Loss $10M, Adj. EPS $(1.15), Sales ~$250M
Atricure Sees Q1 Sales $55M-$57M vs $59.3M Estimate, Adj. EPS $(0.39)-$(0.36)

Conference Call Details

Date: Feb 23, 2021

Time: 04:30 PM

View more earnings on ATRC

ET Webcast URL: https://edge.media-server.com/mmc/p/7888agea

Technicals

52-week high: $67.01

52-week low: $23.16

Price action over last quarter: Up 69.55%

Company Overview

AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.